Latest Breaking News On - Leidos biomedical research - Page 11 : comparemela.com
E-Mail
The National Cancer Institute s Genomic Data Commons (GDC), launched in 2016 by then-Vice President Joseph Biden and hosted at the University of Chicago, has become one of the largest and most widely used resources in cancer genomics, with more than 3.3 petabytes of data from more than 65 projects and over 84,000 anonymized patient cases, serving more than 50,000 unique users each month.
In new papers published Feb. 22 in
Nature Genetics, the UChicago-based research team shares new details about the GDC, which is funded by the National Cancer Institute (NCI), via subcontract with the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc. One of the papers describes the design and operation of the GDC. The other describes the pipelines used by the GDC for the harmonization of data submitted to the GDC and the generation of datasets used by the GDC research community.
Joseph-biden
Robert-grossman
Leidos-biomedical-research-inc
Nature-communications
National-cancer-institute
National-institutes-of-health
Cancer-center
Sciences-division
University-of-chicago-medical-center
National-cancer-institute-genomic-data-commons
University-of-chicago-medicine-biological-sciences
Frederick-national-laboratory-for-cancer-research
E-Mail
WASHINGTON - Pancreatic cancer, one of the most lethal of all cancers, is capable of evading attacks by immune cells by changing its microenvironment so that the immune cells suppress, rather than support, an attack on the tumor. The scientists also found that that some of the mediators of this suppressive response, including a protein called STAT1, represent potential therapeutic targets that could be used to reverse this evasion and point to possible treatment opportunities.
The finding appears January 28, 2021, in
Cancer Immunology Research. This is the first demonstration that an immune attack induces pancreatic cancer-derived immune suppression, offering a new approach to immunotherapy for this deadly cancer, noted Louis M. Weiner, M.D., director of Georgetown Lombardi and the Principal Investigator of this study.
Lombardi-cancer-center
District-of-columbia
United-states
Johns-hopkins-university
Maryland
Department-of-energy
Washington
Saudi-arabia
Oak-ridge
Georgetown-university
Baltimore
Saudi-arabian